Abstract
During the last decades multidrug resistance (MDR) emerged as main problem in the anti-cancer therapy with cytostatically active agents. Classical as well as recently developed cytostatics develop the phenomenon of loosing activity in former drug-sensitive cells. Although MDR is a multifactorial process, the main obstacle is the expression of multidrug-efflux pumps that lowers the intracellular drug levels. P-glycoprotein (P-gp) is the longest identified efflux pump. As the attempt to overcome MDR by the use of inhibitors of the efflux pump activities turned out as most promising effect, the development of P-gp inhibitors has been a challenge for medicinal chemists. The article reviews the advances in P-gp inhibitor development by focussing on structure-activity relationships in the different compound classes to document improvements. The success has been the reduction of cytotoxic properties. The undesired activities could be much lowered in the case of compound classes that were derived from pharmacologically active drugs. Undesired drug interactions and limited in vivo activities are still a problem.
Keywords: Multidrug resistance, P-gp inhibitor, development
Anti-Cancer Agents in Medicinal Chemistry
Title: Recent Advances in the Development of P-gp Inhibitors
Volume: 9 Issue: 4
Author(s): Christiane Baumert and Andreas Hilgeroth
Affiliation:
Keywords: Multidrug resistance, P-gp inhibitor, development
Abstract: During the last decades multidrug resistance (MDR) emerged as main problem in the anti-cancer therapy with cytostatically active agents. Classical as well as recently developed cytostatics develop the phenomenon of loosing activity in former drug-sensitive cells. Although MDR is a multifactorial process, the main obstacle is the expression of multidrug-efflux pumps that lowers the intracellular drug levels. P-glycoprotein (P-gp) is the longest identified efflux pump. As the attempt to overcome MDR by the use of inhibitors of the efflux pump activities turned out as most promising effect, the development of P-gp inhibitors has been a challenge for medicinal chemists. The article reviews the advances in P-gp inhibitor development by focussing on structure-activity relationships in the different compound classes to document improvements. The success has been the reduction of cytotoxic properties. The undesired activities could be much lowered in the case of compound classes that were derived from pharmacologically active drugs. Undesired drug interactions and limited in vivo activities are still a problem.
Export Options
About this article
Cite this article as:
Baumert Christiane and Hilgeroth Andreas, Recent Advances in the Development of P-gp Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/1871520610909040415
DOI https://dx.doi.org/10.2174/1871520610909040415 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Histidine Rich Glycoprotein, an Endogenous Regulator of Macrophage and Endothelial Biology
Current Angiogenesis (Discontinued) The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations
Current Medicinal Chemistry The Mevalonate Pathway and Innate Immune Hyper-Responsiveness in the Pathogenesis of COPD and Lung Cancer: Potential for Chemoprevention
Current Molecular Pharmacology Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Prospects of Applying Enhanced Semi-Empirical QM Methods for 2101 Virtual Drug Design
Current Medicinal Chemistry Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry Anti-Proliferative Activities of Terpenoids Isolated from Alisma orientalis and their Structure-Activity Relationships
Anti-Cancer Agents in Medicinal Chemistry Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry Clinical Advances in Bone Regeneration
Current Stem Cell Research & Therapy BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds
Current Cancer Drug Targets Does More MnSOD Mean More Hydrogen Peroxide?
Anti-Cancer Agents in Medicinal Chemistry Cancer Chemoprevention by Garlic and Its Organosulfur Compounds-Panacea or Promise?
Anti-Cancer Agents in Medicinal Chemistry The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Patent Selections :
Recent Patents on Biomarkers Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry Generation of a Chimeric Plasmin-resistant VEGF165/VEGF183 (132-158) Protein and its Comparative Activity
Protein & Peptide Letters Preparation of Water-Soluble Albumin Loaded Paclitaxil Nanoparticles Using Emulsion-Solvent Evaporation Technique
Current Bioactive Compounds Targeting 5-Lipoxygenase Signaling Pathways to Reverse Drug Resistance in Cancer
Letters in Drug Design & Discovery Meet Our Editorial Board Member
Current Cancer Drug Targets